Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) had its price target raised by Evercore ISI from $25.00 to $30.00 in a research report report published on Wednesday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the stock. A number of other equities research analysts have also commented on KNSA. Wedbush restated an outperform […]
Wedbush reaffirmed their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) in a research note published on Tuesday morning, RTT News reports. They currently have a $30.00 price objective on the stock. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.02) EPS, Q4 […]
Linden Thomas Advisory Services LLC cut its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 1.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 114,550 shares of the company’s stock after selling 1,341 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Kiniksa Pharmaceuticals were worth $2,009,000 as of […]
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Wednesday, February 28th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.17) per share for the quarter. Wedbush […]
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.94 and last traded at $20.83, with a volume of 197612 shares traded. The stock had previously closed at $20.16. Analyst Ratings Changes KNSA has been the topic of […]